Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus CapeOX in advanced GC/GEJC with high TMEscore
NCT06202716Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Progression-free Survival at 3 years. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06202716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202716.